• 한국응급구조학회지
• /
• 제26권1호
• /
• pp.119-127
• /
• 2022

Purpose: This study aimed to examine the necessity of administrative compensation insurance and claims cases during the emergency medical service process among administrative compensation insurance cases and suggests problems and improvement measures. Methods: We compared the details of administrative compensation insurance claims of 15 cities and provinces, excluding Seoul and Kwangju, from 2017 to 2020 by requesting details disclosure of the comprehensive deduction for administrative compensation in 17 cities and provinces across the country. Results: A total of 69 cases were compensated through the administrative comprehensive compensation deductions. There were 53 cases of damage that occurred at the field stage, 14 cases at the transfer and hospital stage, and two other cases. Conclusion: The 119 paramedics, which are the perpetrators, should be active in field activities and free from the psychological pressure caused by increased workload and litigation. Active compensation administration is required for damage cases occurring in the firefighting activities context.

• 한국지하수토양환경학회지:지하수토양환경
• /
• 제14권3호
• /
• pp.14-21
• /
• 2009

미국 환경법에 규정된 Imminent & Substantial Endangerment(ISE) 조항에 대한 정의, 결정 및 적용사례를 분석하였다. ISE는 행정권자가 현재의 환경오염상황이 인체에 급박하고 실질적인 위해를 가할 수 있는 오염으로 판단할 경우 오염책임자에게 대책을 강구하게 하는 환경오염 상황 및 환경법상의 조항으로 정의된다. 이때의 행정권자의 대책 요구는 권고, 행정명령, 민사소송, 형사소송 등 다양하게 이루어지며 모든 행정 집행 과정에 ISE가 언급된다. ISE의 판단을 위해서는 1) a possible ISE 2) because of actual or threatened release 3) of a hazardous substance 4) from a facility, 네 가지 요소에 대한 명확한 증거가 있어야 한다. 그러나 네 가지 요소에 대한 정의는 매우 광범위하며 유연성을 가지고 있어, ISE 판단은 행정권자의 충분한 자료 확보와 주관적인 판단에 따르는 것으로 나타났다. 또한 ISE 판단은 판단 주체에 따라 차이를 보이지만 공통적인 사항은 매우 상세한 현장조사 결과 및 과학적인 정황에 기인하고 있다. 미국내 ISE 행정명령에 대한 기본 문서 형태 및 내용은 규정되어 있지만 ISE 판단에 대한 구체적인 정량적 기준 및 방법은 정의되어 있지 않았다.

• 보건행정학회지
• /
• 제1권1호
• /
• pp.72-94
• /
• 1991

The number of disputes between physicians and patients caused by medical malpractice are showing a sharp increasing over the past several years. The disputes on medical malpractice may be resolved either in court or by direct negotiation between both sides concerned. There are no special acts relating to the civil or penal liability of the physicians in Korea. The medical disputes are decided merely through legal technicalities and without reference to actual medical practice. The current system which does not compensate injured patients adequately or equitably leads to taking a long time consuming for dispute resolution processes. The things make worsed, the problem is due to not being of insurance system or a proper funds for compensation. This research proposes a outline of new and comprehensive alternative for these problems and failure of conventional resolution of medical disputes. So far, we have learned lessons from the excperiencies of resolving medical malpractice disputes of Japan and the United States. The proposal first calls for an administrative arbitration and pretrial screening panels as a condition precedent to trial. The proposal also includes to facilitate with the funds for compensating the injured.

• 보건행정학회지
• /
• 제13권4호
• /
• pp.48-65
• /
• 2003

Detailed analyses of total health expenditure and its sub­categories are essential for the evidence­based health policy(EBHP). These analyses, again, should be based on timely and reliable data that are comparable across countries. The System of Health Accounts (SHA), published by the OECD in 2000, provides an integrated system of comprehensive and internationally comparable accounts. The author has implemented the SHA manual into Korean situation, and examined overall expenditure estimate and its basic functional breakdown following the manual. This study explains how pharmaceutical expenditure is estimated. The results are, then, analyzed particularly from the international perspective. Both administrative data in Statistical Yearbooks (National Health Insurance, Medical Aid, Industrial Accident Compensation Insurance) and survey data on Health and Nutrition are used for the estimation. Per capita pharmaceutical expenditure in Korea (183 US$ PPPs) was far less than the OECD average (308 US$ PPPs) in 2001, but pharmaceutical expenditure share in total health expenditure (20.3％) was higher than the average (16.7％). This can be explained by the fact that there is a statistically significant correlation between pharmaceutical expenditure share and per capita GDP of each country. Korean people follow the tendency of relatively low­income countries to spend less than OECD average for health care, but follow again their tendency to spend more on drugs than on other health care services. In consideration of results and analysis as above, per capita pharmaceutical expenditure in Korea is expected to grow in the future, but the growth rate of the pharmaceutical expenditure is expected to be less than that of overall health expenditure.